Amaryl M 2mg
Generic: Metformin/Glimepirideby Sanofi India Limited

Similar medicines
View allAbout Amaryl M 2mg
Amaryl M 2mg is a Sanofi India tablet that combines two type 2 diabetes medicines in one bilayer tablet: 2 mg of glimepiride, a sulfonylurea, and 500 mg of metformin hydrochloride in a prolonged release layer. The "2mg" in the name is the glimepiride part only; every Amaryl M 2mg tablet also carries 500 mg of metformin. We sell it in packs of 100, 200 and 300 tablets, from $0.57 a tablet in the largest pack.
Two points before you read further. First, Sanofi's Indian prescribing information says Amaryl M is for people whose diabetes is not controlled by diet, exercise and one medicine alone, and that the first dose should not be more glimepiride or metformin than you already take. It is not a tablet to start on your own: it needs a doctor, regular blood glucose and HbA1c checks, and kidney tests. Second, in the US the same two medicines are sold as separate generic tablets that cost far less per day than our combination tablet. This page sets out the doses, the warnings and the price per tablet, using Sanofi's Indian prescribing information (December 2025), current US labels for glimepiride and extended release metformin, and UK product information, all listed at the end.
Amaryl M 2mg at a glance
| Active ingredients | Glimepiride 2 mg plus metformin hydrochloride 500 mg (prolonged release), per tablet |
| Brand and maker | Amaryl M, Sanofi India Limited (Goa plant named in the Indian prescribing information); distributed in India by Emcure Pharmaceuticals since July 2025 |
| Drug classes | Sulfonylurea (glimepiride) and biguanide (metformin) |
| Regulatory status | Amaryl M is not approved by the FDA, MHRA, TGA or Health Canada. We found no glimepiride plus metformin combination tablet licensed in the US, Canada, the UK or Australia. India approved the combination in 2002 |
| Usual dose from the label | One tablet once a day with breakfast or the first main meal to start (Sanofi India abridged PI), and never more glimepiride or metformin than you already take; your doctor sets the dose from your blood glucose |
| Timing | In healthy volunteers, glimepiride's lowest blood glucose came about 2 to 3 hours after a single dose (US glimepiride label 12.2) |
| Packs | 100, 200 and 300 tablets (Indian strips hold 15 or 20) |
| Price per tablet | $0.64 (100 pack) down to $0.57 (300 pack), before shipping |
| Delivery | 7 to 14 business days to the US, UK, Australia and Canada; $25 shipping under $149, free from $149 |
Price per tablet
Prices below are as of October 2026. The pack selector above always shows the current price.
| Pack | Price | Per tablet | Shipping | Per tablet with shipping |
|---|---|---|---|---|
| 100 tablets | $64 | $0.64 | $25 | $0.89 |
| 200 tablets | $120 | $0.60 | $25 | $0.73 |
| 300 tablets | $170 | $0.57 | Free | $0.57 |
The 300 pack is cheaper per tablet before shipping as well, and it also clears the $149 free shipping line. How long a pack lasts depends on the dose your doctor sets. Our estimate:
| Pack | At 1 tablet a day | At 2 tablets a day |
|---|---|---|
| 100 tablets | 100 days (about 3 months) | 50 days |
| 200 tablets | 200 days (about 6.5 months) | 100 days |
| 300 tablets | 300 days (about 10 months) | 150 days |
Diabetes doses often change, and kidney function can change too. Before you buy a large pack, check with your doctor that your dose is settled, and check the expiry date on the strips when they arrive.
Compared with US generics
| Amaryl M 2mg (ours) | US generic glimepiride 2 mg plus generic metformin ER 500 mg | |
|---|---|---|
| What you take | One combination tablet | Two separate tablets |
| Maker | Sanofi India | Several US generic makers |
| FDA approved | No | Yes, each as a single-ingredient tablet |
| Cost per day for 2 mg plus 500 mg | $0.57 to $0.64 before shipping | About $0.07 (NADAC: $0.03752 plus $0.02838) |
NADAC is the average price US pharmacies pay to buy a medicine, published by the US Medicaid programme; it is not the price a patient pays at the counter. The figures above are the rows for generic glimepiride 2 mg tablets ($0.03752 each) and generic metformin ER 500 mg tablets ($0.02838 each), effective 23 September 2026. NADAC is not a retail price, but the gap is large: about $0.07 a day for the two generics against $0.57 to $0.64 for our tablet before shipping. If you are in the US and have a prescription, compare US generic cash prices first.
There is no US version of this combination to compare. The FDA's database lists no glimepiride plus metformin tablet, and Sanofi's US Amaryl and the US Glucophage and Glucophage XR brands are all listed as discontinued; the FDA notes for each that it was not discontinued for reasons of safety or effectiveness. US doctors can prescribe other sulfonylurea plus metformin combinations, glipizide with metformin and glyburide with metformin, as generics (NADAC about $0.17 to $0.24 a tablet). These are different sulfonylureas, not substitutes you can switch to without your doctor.
Which strength to choose
| Product | Glimepiride | Metformin (prolonged release) | How it fits the label |
|---|---|---|---|
| Amaryl M 1mg | 1 mg | 500 mg | Contains the 1 mg glimepiride starting dose that the US glimepiride label sets for older people and people with kidney impairment |
| Amaryl M 2mg | 2 mg | 500 mg | For people already taking at least 2 mg glimepiride and 500 mg metformin a day |
| Amaryl M Forte 1mg | 1 mg | 1000 mg | More metformin per tablet, low glimepiride |
| Amaryl M Forte 2mg | 2 mg | 1000 mg | More metformin per tablet |
Compositions are from Sanofi India's prescribing information for Amaryl M and Amaryl M Forte. Sanofi's Indian label sets a top daily dose of 8 mg glimepiride and 2000 mg metformin, and adds that glimepiride doses above 6 mg a day "are more effective only in a minority of patients". The UK glimepiride label sets 6 mg a day as its maximum; the US label sets 8 mg. Because each Amaryl M 2mg tablet carries 500 mg of metformin, four tablets already reach the 2000 mg metformin limit. Four tablets also give 8 mg of glimepiride, the top dose in Sanofi's and the US label and above the UK maximum of 6 mg. Glimepiride alone is sold as Amaryl 1mg, Amaryl 2mg and Amaryl 3mg.
The limit of a fixed combination. With separate tablets, a doctor can raise or lower glimepiride without touching metformin, and the other way round. With Amaryl M, every tablet you add or remove changes both medicines together. Sanofi's label says the dose should be changed one tablet at a time, and that if no Amaryl M strength fits, the two medicines "should be used" as separate tablets instead. Glimepiride needs may also fall as diabetes control improves, so the label says a timely dose reduction or stopping "must therefore be considered" to avoid low blood sugar.
How to take Amaryl M 2mg
- Take it exactly as your doctor prescribes. Sanofi's label says Amaryl M is taken once a day during breakfast or the first main meal, and the starting dose should not exceed the glimepiride or metformin you already take.
- Swallow the tablet whole. Because the metformin layer is prolonged release, the label says Amaryl M "must be swallowed whole and not crushed or chewed".
- Do not skip the meal. Skipped meals, irregular mealtimes and alcohol with a skipped meal are among the label's listed causes of low blood sugar.
- If you forget a dose, the label says the mistake "must never be corrected by subsequently taking a larger dose". Agree with your doctor in advance what to do after a missed dose or a missed meal.
- Check your blood glucose as your doctor advises. The label says blood glucose must be measured regularly during treatment and recommends regular HbA1c tests.
- Have your kidney function (eGFR) tested before starting and at least once a year (Sanofi India, renal impairment; US metformin label 5.1). Sanofi suggests every 3 to 6 months for older people and those whose kidney function is falling.
- Tell any doctor who plans an X-ray or scan with iodinated contrast dye, or surgery, that you take metformin (see below).
- Never start, stop, switch or combine diabetes medicines on your own. If you are on separate glimepiride and metformin tablets now, only your doctor can decide whether Amaryl M 2mg matches your doses.
Lower doses and extra care for some groups
- Kidney impairment. Sanofi's label limits metformin to 2000 mg a day at an eGFR of 45 to 59 mL/min and 1000 mg a day (two Amaryl M 2mg tablets) at 30 to 44, with the starting dose at most half the maximum in both bands. Below 30, metformin is contraindicated and the label says a change to insulin is indicated. The US metformin label says starting metformin at an eGFR of 30 to 45 "is not recommended". The US glimepiride label sets a starting dose of 1 mg of glimepiride for all patients with kidney impairment, so Amaryl M 2mg is not suitable for someone in this group who is starting glimepiride.
- Older people. The US glimepiride label says patients at increased risk of low blood sugar, such as the elderly, "should be started on 1 mg once daily", and that low blood sugar may be hard to recognise in older people. So Amaryl M 2mg is not suitable for someone in this group who is starting glimepiride. The US metformin label says to check kidney function more often in older people.
- Liver problems. Sanofi's label lists hepatic insufficiency as a contraindication to the metformin part, and says that with severe liver impairment a change to insulin is indicated. The US metformin label says it is "not recommended" with liver impairment.
- Illness, injury, surgery and fever. Sanofi's label says blood glucose control may deteriorate in these situations, and a temporary change to insulin may be needed. If you have vomiting, severe diarrhoea, fever or cannot drink, the label says metformin should be stopped for a while and you should contact a health professional.
- Changing from a long-acting sulfonylurea such as chlorpropamide: the US glimepiride label says the effects can overlap for 1 to 2 weeks, with monitoring for low blood sugar.
Low blood sugar (hypoglycaemia)
Low blood sugar is the main day to day risk of the glimepiride part. The US glimepiride label states: "All sulfonylureas, including glimepiride, can cause severe hypoglycemia", which "can lead to unconsciousness or convulsions and may result in temporary or permanent impairment of brain function or death." In one 22 week US trial in which glimepiride was adjusted to a fasting glucose target, 19.7% of people on glimepiride had possible hypoglycaemia against 3.2% on placebo. In a US trial of extended release metformin added to glyburide, another sulfonylurea, hypoglycaemia was reported by 14% against 5% with placebo plus glyburide.
Who is more at risk (Sanofi India and US glimepiride label): older people; kidney or severe liver impairment; skipped or irregular meals, undernourishment or diet changes; more exercise than usual without extra carbohydrate; alcohol, especially with a skipped meal; certain thyroid, pituitary or adrenal disorders; the first weeks of treatment; other diabetes medicines, including insulin; and medicines listed in the interactions section. Warning signs can be weaker or missing in older people, in people with nerve damage (autonomic neuropathy) and in people taking beta blockers, clonidine, reserpine or guanethidine.
Signs listed by Sanofi include headache, strong hunger, nausea, sleepiness, restlessness, aggression, poor concentration, confusion, speech or vision problems, tremor, dizziness, sweating, clammy skin, anxiety, a fast or pounding heartbeat, and in severe cases fits and loss of consciousness. The label adds that a severe attack can look like a stroke.
What to do. The label says low blood sugar "can almost always be promptly controlled by immediate intake of carbohydrates (glucose or sugar)"; the UK glimepiride label adds that artificial sweeteners have no effect. Take glucose tablets, sugar or a sugary drink, then eat, because both labels warn that low blood sugar can come back after you first recover. Severe low blood sugar needs immediate medical treatment; the labels say it can be treated with glucagon or glucose into a vein. If someone is unconscious or cannot swallow, call emergency services; as general first aid, do not put food or drink in their mouth. Because low blood sugar affects concentration and reactions, the labels warn about driving or using machinery, especially early in treatment or after a dose change.
Lactic acidosis
US metformin labels carry a boxed warning for lactic acidosis, a rare build-up of acid in the blood. The current US extended release metformin label says postmarketing cases "have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias", and that the onset "is often subtle". Sanofi's Indian label gives a rate of 0.03 cases per 1000 patient-years and calls it very rare.
The US label lists these risk factors: kidney impairment, some medicines (for example carbonic anhydrase inhibitors such as topiramate), age 65 or older, X-ray studies with contrast dye, surgery and other procedures, low oxygen states such as acute heart failure, excessive alcohol and liver impairment. Sanofi adds dehydration, prolonged fasting, poorly controlled diabetes and ketosis.
Symptoms (US patient information): feeling very weak and tired, unusual sleepiness, unusual muscle pain, trouble breathing, feeling cold in the arms and legs, dizziness or lightheadedness, unexplained stomach problems with nausea, vomiting or diarrhoea, and a slow or irregular heartbeat. The patient information says: stop taking the medicine and call your doctor right away; lactic acidosis "is a medical emergency and must be treated in the hospital".
Contrast dye and surgery. Sanofi's label says metformin should be stopped before, or at the time of, an imaging procedure with iodinated contrast and not restarted for at least 48 hours, once kidney function has been rechecked and found stable. It must also be stopped at the time of surgery under general, spinal or epidural anaesthesia, and restarted no earlier than 48 hours after surgery or after you are eating again, with kidney function rechecked. The US label sets out the contrast rule by eGFR (30 to 60), liver disease, alcoholism, heart failure and contrast given into an artery.
Side effects
Sanofi's label says taking the two medicines as a fixed combination has the same safety profile as taking each one separately. The table brings together label figures for each medicine; they come from separate trials and are not a head to head comparison.
| Effect | How often | Source |
|---|---|---|
| Stomach and gut effects (nausea, vomiting, diarrhoea, stomach pain, loss of appetite), mostly at the start | Very common (more than 10%) | Sanofi India, metformin |
| Possible hypoglycaemia, glimepiride vs placebo, 22 weeks | 19.7% vs 3.2% | US glimepiride label 6.1 |
| Hypoglycaemia, metformin ER plus glyburide vs placebo plus glyburide | 14% vs 5% | US metformin ER label, Table 1 |
| Diarrhoea, same trial | 13% vs 6% | US metformin ER label, Table 1 |
| Nausea, same trial | 7% vs 4% | US metformin ER label, Table 1 |
| Headache, glimepiride vs placebo (11 pooled trials) | 8.2% vs 7.8% | US glimepiride label, Table 1 |
| Accidental injury, same trials | 5.8% vs 3.4% | US glimepiride label, Table 1 |
| Dizziness, same trials | 5.0% vs 2.4% | US glimepiride label, Table 1 |
| Fall of vitamin B12 to below normal, 29 week trials (immediate release metformin trials) | About 7% | US metformin label 5.2 |
| Metallic taste | 3% | Sanofi India, metformin |
| Itching, redness, hives or rash | Under 1% | US glimepiride label 6.1 |
| Raised liver enzyme (ALT over twice normal), glimepiride vs placebo | 1.9% vs 0.8% | US glimepiride label 6.1 |
Selected rows. Glimepiride, like all sulfonylureas, can cause weight gain. Other reports in the labels, without a reliable frequency, include temporary vision changes at the start of treatment as blood glucose changes, hepatitis and liver failure, blood disorders (including very low platelets), haemolytic anaemia, low blood sodium, sensitivity to light, hair loss and a changed sense of taste. Long-term metformin can lower vitamin B12, which can cause nerve damage (peripheral neuropathy); the US label advises a blood count every year and a B12 test every 2 to 3 years, and Sanofi recommends B12 monitoring.
The sulfonylurea heart warning. US glimepiride labels carry a special warning on increased risk of cardiovascular death with sulfonylureas, based on the UGDP study, in which patients on tolbutamide for 5 to 8 years had a cardiovascular death rate about 2.5 times that of diet alone. The label notes "controversy regarding the interpretation of these results", and says the warning may also apply to other sulfonylureas. US labels for both medicines also say no study has shown conclusive evidence that they reduce heart and blood vessel disease. Ask your doctor what this means for you.
When to get urgent help
Get emergency help, or ask someone to call for you, if you have:
- Low blood sugar that does not improve after taking sugar, comes back, or causes confusion, fits, fainting or loss of consciousness. The UK glimepiride label says low blood sugar after an overdose can last 12 to 72 hours and may not start for up to 24 hours.
- Signs of lactic acidosis: severe weakness or tiredness, unusual sleepiness, muscle pain, trouble breathing, feeling cold, dizziness, a slow or irregular heartbeat, or stomach pain with vomiting. Sanofi's label says to stop taking metformin and seek immediate medical attention.
- Unusual bruising or bleeding, which can mean a very low platelet count (Sanofi India).
- Swelling of the lips, tongue, face or throat, trouble breathing or swallowing, hives, a spreading rash, or blistering or peeling skin. The US label reports anaphylaxis, angioedema and Stevens-Johnson syndrome; stop the tablets and get treatment.
- Yellow skin or eyes, dark urine or pale stools, which can mean liver injury.
- Taking more than your prescribed dose. Sanofi's label says a doctor "must be notified without delay" and you should take sugar straight away; the metformin part can also cause lactic acidosis in overdose.
Tell the emergency staff that you took glimepiride and metformin (Amaryl M), how much and when.
If vomiting, severe diarrhoea, fever or not drinking enough leaves you dehydrated, Sanofi's label says metformin should be stopped for a while and you should contact a health professional. Because Amaryl M contains both medicines, and not eating raises the risk of low blood sugar from glimepiride, ask your doctor straight away what to do with your tablets.
Who should not take Amaryl M 2mg
Never take it if (Sanofi India contraindications for Amaryl M, unless another label is named):
- you are allergic to glimepiride, other sulfonylureas, other sulfonamides, metformin or any ingredient of the tablet. The US glimepiride label also says do not use it if you have had an allergic reaction to sulfonamide derivatives.
- you have diabetic ketoacidosis, diabetic pre-coma or any acute metabolic acidosis, including lactic acidosis. The US metformin label also lists metabolic acidosis, including diabetic ketoacidosis, as a contraindication.
- you have type 1 diabetes: the UK glimepiride label lists it as a contraindication, and the US glimepiride label says glimepiride should not be used for type 1 diabetes or diabetic ketoacidosis because it would not be effective.
- your eGFR is below 30 mL/min (severe kidney failure)
- you have an acute condition that can affect the kidneys, such as dehydration, severe infection or shock, or are having iodinated contrast dye injected into a blood vessel
- you have a condition that can starve tissues of oxygen, such as heart or lung failure, a recent heart attack or shock
- you have impaired liver function (hepatic insufficiency), are drunk (acute alcohol intoxication) or have alcoholism
- you are pregnant or breastfeeding
Not recommended or use only with care:
- Known mitochondrial disease such as MELAS or MIDD: Sanofi says Amaryl M "is not recommended".
- Starting metformin at an eGFR of 30 to 45: "not recommended" (US metformin label).
- G6PD deficiency: sulfonylureas can cause haemolytic anaemia; the labels say use caution and consider a non-sulfonylurea alternative.
- Heart failure: Sanofi's Amaryl M label lists heart failure as a contraindication. The UK Glucophage SR label allows metformin alone in stable chronic heart failure with regular heart and kidney checks, but that applies to metformin on its own, not to this combination tablet. Only your doctor can decide.
- Hypothyroidism: Sanofi recommends regular TSH monitoring.
- Children and teenagers: Sanofi says data are insufficient to recommend use; the US glimepiride label says it is "not recommended" in children.
Pregnancy and breastfeeding. Sanofi's label says glimepiride "must not be taken during pregnancy" and the patient "must change over to insulin"; women planning a pregnancy must tell their doctor, and Sanofi recommends changing to insulin. For the metformin part, Sanofi's label also says diabetes should not be treated with metformin when planning a pregnancy or during pregnancy; insulin should be used. The UK glimepiride label also says to switch to insulin. The 2025 UK Glucophage SR label says metformin alone can be considered in pregnancy as an addition or an alternative to insulin; that applies to metformin taken on its own and does not apply to this combination tablet. The US glimepiride label says to stop glimepiride at least two weeks before the expected delivery because of reports of prolonged severe low blood sugar in newborns. Sanofi's label says glimepiride must not be taken while breastfeeding.
Medicines that interact
- Medicines that can increase the sugar-lowering effect (risk of low blood sugar): insulin and other diabetes tablets, ACE inhibitors, fluconazole and miconazole, clarithromycin, quinolone antibiotics, sulfonamide antibiotics, tetracyclines, fibrates, fluoxetine, MAO inhibitors, salicylates, anabolic steroids and others listed in the labels. The US label says severe low blood sugar has been reported with oral miconazole and sulfonylureas.
- CYP2C9: glimepiride is broken down by the CYP2C9 enzyme. Fluconazole may raise glimepiride levels; rifampicin may lower them.
- Medicines that can weaken the effect (higher blood sugar): corticosteroids, thiazide and other diuretics, thyroid hormones, oestrogens and the contraceptive pill, phenytoin, nicotinic acid, phenothiazines, some antipsychotics, sympathomimetics such as salbutamol (albuterol) and adrenaline, and rifampicin.
- Beta blockers, clonidine, reserpine and guanethidine can hide the warning signs of low blood sugar, and beta blockers can make the effect stronger or weaker.
- Alcohol: it can make glimepiride's effect stronger or weaker unpredictably and raises the lactic acidosis risk with metformin. Sanofi says to avoid alcohol and medicines that contain alcohol.
- Carbonic anhydrase inhibitors (topiramate, zonisamide, acetazolamide) may increase the lactic acidosis risk (US metformin label).
- Medicines that reduce metformin clearance (OCT2 or MATE inhibitors), such as ranolazine, vandetanib, dolutegravir, cimetidine and trimethoprim, can raise metformin levels.
- Medicines that can affect the kidneys, such as NSAID painkillers, ACE inhibitors, angiotensin receptor blockers and diuretics: Sanofi advises close monitoring of kidney function.
- Colesevelam: take glimepiride at least 4 hours before it.
- Warfarin and similar coumarin blood thinners: the effect may be stronger or weaker; Sanofi advises close INR monitoring with phenprocoumon.
Tell your doctor or pharmacist about every medicine and supplement you take before you start, and before you start anything new.
Prescription and legal status
In India, the regulator (DCG(I)) approved glimepiride 1 mg or 2 mg with metformin 500 mg SR tablets on 13 November 2002, and a 1000 mg metformin strength in June 2007. Sanofi's prescribing information is marked for registered medical practitioners, and the Indian pharmacy listings we checked (Truemeds, MediBuddy) mark Amaryl M 2mg as prescription required.
In the US, glimepiride and metformin are prescription medicines, sold as separate generic tablets; there is no FDA-approved glimepiride plus metformin tablet, and the FDA says personal importation of unapproved medicines is illegal in most circumstances. In Canada, the Health Canada Drug Product Database lists no glimepiride plus metformin product; Sanofi's Amaryl was cancelled in 2018, and generic glimepiride is marketed as a prescription medicine. In Australia, healthdirect lists several glimepiride brands but no metformin combination, Amaryl's ARTG entries are cancelled, and glimepiride is a Schedule 4 (prescription only) medicine. In the UK, we found no glimepiride plus metformin product and no Amaryl listing on the electronic medicines compendium, which is not the full MHRA register; glimepiride and metformin are licensed separately, and the NHS says metformin is only available with a prescription. Amaryl M itself is not licensed by the FDA, the MHRA, the TGA or Health Canada. Check the rules where you live.
Buying genuine Amaryl M
The MHRA warns that "Any medicine not authorised for sale in the UK can be unsafe or ineffective and there is no way of knowing what is in them or the negative health effects they can have", and it advises UK buyers to use only UK-registered pharmacies. That warning covers Amaryl M, which is not authorised in the UK. When your order arrives, read the strip: it should say Amaryl M 2mg and list glimepiride 2 mg and metformin hydrochloride 500 mg in prolonged release form, with a batch number and an expiry date. Indian listings name Sanofi India; PharmEasy's listing names Emcure Pharmaceuticals, which has distributed Sanofi India's oral diabetes brands since July 2025. These checks cannot prove that tablets are genuine, because counterfeiters copy packaging. Check your blood glucose closely during the first weeks on any new supply, and tell your doctor if your readings change. If a batch causes unusual symptoms, seek medical advice and report it to your medicines regulator (the MHRA Yellow Card scheme in the UK, FDA MedWatch in the US, the TGA in Australia or Health Canada) as well as to us.
Delivery
We ship Amaryl M 2mg to the US, UK, Australia and Canada in plain packaging with tracking. Standard delivery takes 7 to 14 business days to most countries. Shipping costs a flat $25 on orders under $149 and is free from $149. Diabetes tablets should not run out: order well before your current supply ends, and do not stop or ration your tablets while you wait. See our shipping page and refund policy.
Related guides
- Metformin vs glimepiride: how the two most prescribed oral diabetes tablets differ
- Buy Amaryl (glimepiride) online: dosing, hypoglycaemia risk and what to verify first
- Metformin dosage guide: starting doses, titration steps and maximum daily limits
- Metformin side effects: trial incidence rates, GI timing and B12 monitoring
Other strength: Amaryl M 1mg.
Sources
- Sanofi India Limited. Metformin Hydrochloride Prolonged Release and Glimepiride Tablets I.P. (Amaryl M 1mg, Amaryl M 2mg), prescribing information, updated December 2025: composition, indication, dosage and administration (renal table), contraindications, warnings, precautions, interactions, pregnancy, lactation, adverse reactions, overdosage. Sanofi India
- Sanofi India Limited. Amaryl M 1mg and 2mg, abridged prescribing information, December 2025: initial dose, maximum dosing, contraindications. Sanofi India
- Sanofi India Limited. Amaryl M Forte 1mg and 2mg, abridged prescribing information, December 2025: composition. Sanofi India
- Sanofi India Limited and Emcure announce exclusive distribution partnership for Sanofi's oral anti-diabetic drugs, press release, 16 July 2025. Sanofi India
- Glimepiride tablets USP, US prescribing information, Aurobindo Pharma, revised March 2026 (DailyMed setid 28eefc95-d92e-4555-b6c5-2933860b0610): sections 1, 2.1, 4, 5.1 to 5.5, 6.1, 6.2, 7, 8.1, 8.2, 8.4 to 8.6, 10, 12.2. DailyMed
- AMARYL (glimepiride) tablets, US prescribing information, sanofi-aventis U.S., revised December 2018 (last label before discontinuation). FDA label PDF
- Metformin hydrochloride extended-release tablets, US prescribing information and patient information, Granules Pharmaceuticals (DailyMed setid a5980bc8-8de8-c456-e053-2a95a90a792e, SPL version 5, October 2026): boxed warning, sections 2.1 to 2.3, 4, 5.1 to 5.4, 6.1, 7, 8.1, 8.2, 8.5 to 8.7, 10. DailyMed
- Glucophage SR 500 mg prolonged release tablets, UK SmPC, Merck, updated 31 March 2025: sections 4.2, 4.3, 4.4, 4.6. emc
- Glimepiride 2 mg tablets, UK SmPC, Brown and Burk, updated 5 January 2021: sections 4.2, 4.3, 4.4, 4.6, 4.8, 4.9. emc
- Central Drugs Standard Control Organisation. Fixed dose combinations approved by DCG(I) since 1961 to 31 December 2019, items 363 (13.11.2002) and 650 (08.06.2007). CDSCO
- US Food and Drug Administration, openFDA drug approvals and NDC directory: glimepiride and metformin products, Amaryl (NDA 020496), Glucophage (NDA 020357) and Glucophage XR (NDA 021202), searched 19 October 2026.
- Centers for Medicare and Medicaid Services. National Average Drug Acquisition Cost (NADAC) 2026: glimepiride 2 mg tablet $0.03752, metformin HCl ER 500 mg tablet $0.02838, glipizide-metformin and glyburide-metformin rows, effective 23 September 2026 (as of 14 October 2026). data.medicaid.gov
- Health Canada Drug Product Database, glimepiride products and status, searched 19 October 2026. Health Canada
- healthdirect Australia, medicines that contain glimepiride, and Amaryl (Schedule 4); TGA ARTG entries for Amaryl glimepiride tablets (cancelled). healthdirect
- NHS. Metformin. NHS
- Indian pharmacy listings for Amaryl M 2mg (PharmEasy, Truemeds, MediBuddy), checked 19 October 2026.
- MHRA. 20 million illegal erectile dysfunction pills seized as MHRA warns against risky online buys, 13 February 2026. GOV.UK
- US Food and Drug Administration. Personal Importation. FDA
This page is for information and is not medical advice. Amaryl M is a prescription diabetes medicine. Take it only as prescribed by a doctor who monitors your blood glucose, HbA1c and kidney function, and do not start, stop or switch diabetes medicines without your doctor.
Frequently asked questions
What is Amaryl M 2mg?
Amaryl M 2mg is a Sanofi India bilayer tablet for type 2 diabetes. Each tablet contains 2 mg of glimepiride, a sulfonylurea, and 500 mg of metformin hydrochloride in prolonged release form. The 2mg in the name is the glimepiride part only. Sanofi's Indian label says it is for people whose blood glucose is not controlled by diet, exercise and one medicine alone. Amaryl M is not approved by the FDA, MHRA, TGA or Health Canada.
Is Amaryl M the same as taking glimepiride and metformin separately?
It contains the same two medicines, and Sanofi's label says the fixed combination has the same safety profile as each medicine taken separately. The difference is flexibility: with separate tablets your doctor can change one dose without the other, while every Amaryl M tablet you add or remove changes both. Sanofi's label says that if no Amaryl M strength fits your doses, the two medicines should be used as separate tablets. Only your doctor should decide whether to switch.
What does Amaryl M 2mg cost per tablet?
As of October 2026 it costs $0.64 a tablet in the 100 pack, $0.60 in the 200 pack and $0.57 in the 300 pack, before shipping. Shipping is $25 under $149 and free from $149, so with shipping a single pack works out at $0.89, $0.73 or $0.57 a tablet. In the US, generic glimepiride 2 mg and generic metformin ER 500 mg had a combined NADAC (pharmacy acquisition cost) of about $0.07 a day, effective 23 September 2026, so US buyers with a prescription should compare US generic cash prices first. The pack selector shows the current price.
How do I take Amaryl M 2mg?
Take it exactly as your doctor prescribes. Sanofi's label says Amaryl M is taken once a day during breakfast or the first main meal, swallowed whole and not crushed or chewed, because the metformin layer is prolonged release. Do not skip the meal. If you forget a dose, the label says never to make up for it by taking a larger dose later; agree a plan for missed doses with your doctor. Check your blood glucose as advised, and have HbA1c and kidney tests as your doctor arranges.
Should I choose Amaryl M 1mg, 2mg or Forte?
That is your doctor's decision, based on the glimepiride and metformin doses you already take. Amaryl M 1mg is glimepiride 1 mg with metformin 500 mg; Amaryl M 2mg is 2 mg with 500 mg; Amaryl M Forte 1mg and 2mg have 1000 mg of metformin. Sanofi's label says the starting dose should not exceed what you already take. The US glimepiride label starts older people and people with kidney impairment on 1 mg of glimepiride, so Amaryl M 2mg is not suitable for someone in these groups who is starting glimepiride.
How long does a pack of Amaryl M 2mg last?
Our estimate: at one tablet a day, the 100 pack lasts 100 days, the 200 pack 200 days and the 300 pack 300 days. At two tablets a day, they last 50, 100 and 150 days. Diabetes doses often change, so check with your doctor that your dose is settled before buying a large pack, and check the expiry date on the strips.
What is the maximum dose of Amaryl M 2mg?
Sanofi's Indian label sets a top daily dose of 8 mg of glimepiride and 2000 mg of metformin, and says glimepiride above 6 mg a day helps only a minority of patients. Because each tablet has 500 mg of metformin, four tablets reach the metformin limit; four tablets also give 8 mg of glimepiride, the top dose in Sanofi's and the US label and above the UK maximum of 6 mg. The UK glimepiride label sets 6 mg a day as the maximum. With kidney impairment the metformin limit is lower: 1000 mg a day at an eGFR of 30 to 44 in Sanofi's label. Never raise your dose yourself.
What are the side effects of Amaryl M 2mg?
The main risks are low blood sugar from glimepiride and stomach upset from metformin. In a 22 week US trial, 19.7% of people on glimepiride had possible hypoglycaemia against 3.2% on placebo. Sanofi lists nausea, vomiting, diarrhoea, stomach pain and loss of appetite as very common with metformin, mostly at the start, and metallic taste in 3%. Other label effects include weight gain, dizziness, headache, low vitamin B12 with long-term use and, very rarely, lactic acidosis, which is a medical emergency.
Who should not take Amaryl M 2mg?
Sanofi's label says not to take it if you are allergic to glimepiride, other sulfonylureas, sulfonamides or metformin; are pregnant or breastfeeding; have diabetic ketoacidosis or other metabolic acidosis; have an eGFR below 30; have dehydration, severe infection, shock or iodinated contrast dye injected into a blood vessel; have heart or lung failure or a recent heart attack; or have impaired liver function, acute alcohol intoxication or alcoholism. The UK glimepiride label also excludes type 1 diabetes. G6PD deficiency needs caution, and Sanofi does not recommend it with mitochondrial disease such as MELAS or MIDD.
Do I need a prescription for Amaryl M 2mg?
Yes, you should have one. Both medicines carry prescription-only labels in the US, glimepiride is prescription-only in Canada and Australia, the NHS says metformin is only available with a prescription in the UK, and Indian listings we checked mark Amaryl M 2mg as prescription required. No glimepiride plus metformin tablet is FDA approved, and the FDA says personal importation of unapproved medicines is illegal in most circumstances. Diabetes treatment also needs regular blood glucose, HbA1c and kidney checks, so do not start or switch without your doctor.
How long does delivery take?
Standard delivery takes 7 to 14 business days to the US, UK, Australia and Canada, in plain packaging with tracking. Shipping is a flat $25 on orders under $149 and free from $149. Order well before your current supply runs out, and do not stop or ration your diabetes tablets while you wait.
Medical References
Sources: U.S. National Library of Medicine (DailyMed, PubMed), openFDA
Related articles
Customer Reviews
No reviews yet. Bought Amaryl M 2mg? Tell other buyers how it went.










